Novacyt (France) Performance
| ALNOV Stock | EUR 0.58 0.01 1.75% |
The company secures a Beta (Market Risk) of -0.77, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Novacyt are expected to decrease at a much lower rate. During the bear market, Novacyt is likely to outperform the market. At this point, Novacyt has a negative expected return of -0.84%. Please make sure to verify Novacyt's treynor ratio, accumulation distribution, as well as the relationship between the Accumulation Distribution and period momentum indicator , to decide if Novacyt performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Novacyt has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in December 2024. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more
| Begin Period Cash Flow | 91.8 M | |
| Total Cashflows From Investing Activities | -5 M |
Novacyt |
Novacyt Relative Risk vs. Return Landscape
If you would invest 108.00 in Novacyt on August 31, 2024 and sell it today you would lose (50.00) from holding Novacyt or give up 46.3% of portfolio value over 90 days. Novacyt is generating negative expected returns and assumes 5.0543% volatility on return distribution over the 90 days horizon. Simply put, 45% of stocks are less volatile than Novacyt, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Novacyt Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Novacyt's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Novacyt, and traders can use it to determine the average amount a Novacyt's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1667
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ALNOV |
Estimated Market Risk
| 5.05 actual daily | 44 56% of assets are more volatile |
Expected Return
| -0.84 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.17 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Novacyt is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Novacyt by adding Novacyt to a well-diversified portfolio.
Novacyt Fundamentals Growth
Novacyt Stock prices reflect investors' perceptions of the future prospects and financial health of Novacyt, and Novacyt fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Novacyt Stock performance.
| Return On Equity | -0.0198 | |||
| Return On Asset | 0.0145 | |||
| Profit Margin | (0.1) % | |||
| Operating Margin | 0.07 % | |||
| Current Valuation | (48.03 M) | |||
| Shares Outstanding | 70.63 M | |||
| Price To Earning | (1.71) X | |||
| Price To Book | 0.43 X | |||
| Price To Sales | 1.02 X | |||
| Revenue | 95.78 M | |||
| EBITDA | (1.71 M) | |||
| Cash And Equivalents | 101.75 M | |||
| Cash Per Share | 0.03 X | |||
| Total Debt | 1.45 M | |||
| Debt To Equity | 26.60 % | |||
| Book Value Per Share | 1.88 X | |||
| Cash Flow From Operations | 15.69 M | |||
| Earnings Per Share | (0.04) X | |||
| Total Asset | 183.7 M | |||
| Retained Earnings | (28 M) | |||
| Current Asset | 7 M | |||
| Current Liabilities | 8 M | |||
About Novacyt Performance
Assessing Novacyt's fundamental ratios provides investors with valuable insights into Novacyt's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Novacyt is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Novacyt S.A. develops and sells diagnostic products for cancer and infectious diseases. The company was founded in 2006 and is based in Vlizy-Villacoublay, France. NOVACYT operates under Biotechnology classification in France and is traded on Paris Stock Exchange. It employs 111 people.Things to note about Novacyt performance evaluation
Checking the ongoing alerts about Novacyt for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Novacyt help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Novacyt generated a negative expected return over the last 90 days | |
| Novacyt has high historical volatility and very poor performance | |
| Novacyt has some characteristics of a very speculative penny stock | |
| The company reported the revenue of 95.78 M. Net Loss for the year was (9.73 M) with profit before overhead, payroll, taxes, and interest of 64.87 M. |
- Analyzing Novacyt's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Novacyt's stock is overvalued or undervalued compared to its peers.
- Examining Novacyt's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Novacyt's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Novacyt's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Novacyt's stock. These opinions can provide insight into Novacyt's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Novacyt Stock Analysis
When running Novacyt's price analysis, check to measure Novacyt's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novacyt is operating at the current time. Most of Novacyt's value examination focuses on studying past and present price action to predict the probability of Novacyt's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novacyt's price. Additionally, you may evaluate how the addition of Novacyt to your portfolios can decrease your overall portfolio volatility.